Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-07-14
2009-02-10
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S314000, C546S159000, C546S160000, C546S161000
Reexamination Certificate
active
07488740
ABSTRACT:
Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
REFERENCES:
patent: 5420135 (1995-05-01), Brown et al.
patent: 5814630 (1998-09-01), Barker et al.
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 6174889 (2001-01-01), Cockerill et al.
patent: 6207669 (2001-03-01), Cockerill et al.
patent: 6391874 (2002-05-01), Cockerill et al.
patent: 6689772 (2004-02-01), Boschelli et al.
patent: 6713485 (2004-03-01), Carter et al.
patent: 7074799 (2006-07-01), Bakthavatchalam et al.
patent: 7304059 (2007-12-01), Bakthavatchalam et al.
patent: 2004/0106616 (2004-06-01), Bakthavatchalam et al.
patent: 2004/0156869 (2004-08-01), Bakthavatchalam et al.
patent: 2006/0089354 (2006-04-01), Bakthavatchalam et al.
patent: 2006/0111337 (2006-05-01), Bakthavatchalam et al.
patent: 2008/0015183 (2008-01-01), Bakthavatchalam et al.
patent: 2 345 486 (2000-07-01), None
patent: WO96/09294 (1996-03-01), None
patent: WO-98/38714 (1998-09-01), None
patent: WO99/35146 (1999-07-01), None
patent: WO-00/18740 (2000-04-01), None
patent: WO 02/22601 (2002-03-01), None
patent: WO 03/062209 (2003-07-01), None
patent: WO 2004/005472 (2004-01-01), None
patent: WO-2004/054582 (2004-07-01), None
patent: WO 2004/055003 (2004-07-01), None
patent: WO 2004/055004 (2004-07-01), None
patent: WO2006/081388 (2006-08-01), None
Temple, J of Med Chem, vol. 11(6), 1216-1218, 1968.
Temple, Carroll, Jr., “Synthesis of Potential Antimalarial Agents. V.1Pyrido[2,3-b]yrazines”, Journal of Medicinal Chemistry, vol. 13, No. 5, pp. 853-857 (1970).
Temple et al., “Synthesis of Potential Antimalarial Agents. II. 6,8-Disbustituted Pyrido[2,3-b]pyrazines,” J. Med. Chem. 11:1216-1218 (1968).
Berger et al., “Substituted 4-Anilino-7-phenyl-3-quinolinecarbonitriles as Src Kinase Inhibitors,” Bioorganic and Medicinal Chemistry Letters 12:2989-2992 (2002).
Johansen, M.E. et al., “TRPV1 Antagonists Elevate Cell Surface Populations of Receptor Protein and Exacerbate TRPV1-Mediated Toxicities in Human Lung Epithelial Cells”,Toxicological Sciences89(1), 278-286 (2006) (Advance Access publication Aug. 24, 2005).
Thomas, Karen C. et al., “Transient Receptor Potential Vanilloid 1 Agonists Cause Endoplasmic Reticulum Stress and Cell Death in Human Lung Cells,”The Journal of Pharmacology and Experimental Therapeutics321(3), 830-838 (2007).
Bolcskei, Kata et al., “Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice,”Pain117, 368-376 (2005).
Helyes, Zsuzsanna et al., “Role of transient receptor potential vanilloid 1 receptors in endotoxin-induced airway inflammation in the mouse,”Am J Physiol Lung Cell Mol Physiol.292(5):L1173-81 (2007).
Banvolgyi, Agnes et al., “Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model,”J Neuroimmunol.169, 86-96 (2005).
Walker, M. et al., “the VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models in Inflammatory and Neuropathic Pain,” The Journal of Pharmacology and Experimental Therapeutics 304:56-62 (2003).
Pomonis, J.D. et al., “N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain,” The Journal of Pharmacology and Experimental Therapautics 306:387-393 (2003).
Gavva, N.R. “AMG 9810 [(E)-3-(4-t-Butylphenyl)-N-2(2,3-dihydrobenzol[b][1,4] dioxin-6-yl)acrylamide], a Novel Vanilloid Receptor 1 (TRPV1) Antagonist with Antihyperalgesic Properties,” The Journal of Pharmacology and Experimental Therapeutics 313:474-484 (2005).
Ognyanov, V.I., “Design of Potent, Orally Available Antagonists of the Transient Receptor Potential Vanilloid 1. Structure-Activity Relationships of 2-Piperazin-1-yl-1 H-benzimidazoles,” Journal of Medicinal Chemistry, (2006).
Copending U.S. Appl. No. 11/883,005, filed Jul. 25, 2007 as the U.S. National Phase of PCT/US2006/002871, Caldwell et al.
Bakthavatchalam Rajagopal
Caldwell Timothy M.
Chenard Bertrand L.
De Lombaert Stephane
Hodgetts Kevin J.
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Neurogen Corporation
Russett Mark D.
Seaman D. Margaret
LandOfFree
Substituted quinolin-4-ylamine analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted quinolin-4-ylamine analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted quinolin-4-ylamine analogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4119882